Concepedia

Anna Maria Mosconi

AM

Statistics

Publications

32

Citations

2.4K

H-Index

21

Active since

1989

Affiliations

Azienda Ospedaliera di Perugia(Current)

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

European Institute of Oncology

University of Perugia

Istituti di Ricovero e Cura a Carattere Scientifico

Anna Maria Mosconi is an author at Azienda Ospedaliera di Perugia specializing in medicine, oncology, and chemotherapy.

ORCID

Publications per year

1989–2023

32

Publications

32

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

, , +17

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

I. Ray-Coquard, Alexandra Léary, Sandro Pignata et al. · Annals of Oncology · 2023 · 339 citations · Full text

, , +15

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

Lucio Crinò, Giorgio V. Scagliotti, M. Marangolo et al. · Journal of Clinical Oncology · 1997 · 308 citations

, , +17

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Sandro Pignata, Domenica Lorusso, Giovanni Scambia et al. · The Lancet Oncology · 2015 · 172 citations · Full text

, , +13

Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial

Lucio Crinò, Anna Maria Mosconi, Giorgio V. Scagliotti et al. · Journal of Clinical Oncology · 1999 · 164 citations

, , +17

1–5 of 32